

Discovery of Dual A β /Tau Inhibitors and Evaluation of Their Therapeutic Effect on a *Drosophila* Model of Alzheimer's Disease

Annachiara Gandini, Ana Elisa Gonçalves, Silvia Strocchi, Claudia Albertini, Jana Janočková, Anna Tramarin, Daniela Grifoni, Eleonora Poeta, Ondrej Soukup, Diego Muñoz-Torrero, Barbara Monti, Raimon Sabaté, Manuela Bartolini, Giuseppe Legname, and Maria Laura Bolognesi*



Cite This: *ACS Chem. Neurosci.* 2022, 13, 3314–3329



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid- β (A β) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulating evidence now suggests that they synergistically contribute to disease pathogenesis. This could not only help explain negative results from anti-A β clinical trials but also indicate that therapies solely directed at one of them may have to be reconsidered. Based on this, herein, we describe the development of a focused library of 2,4-thiazolidinedione (TZD)-based bivalent derivatives as dual A β and Tau aggregation inhibitors. The aggregating activity of the 24 synthesized derivatives was tested in intact *Escherichia coli* cells over-expressing A β_{42} and Tau proteins. We then evaluated their neuronal toxicity and ability to cross the blood–brain barrier (BBB), together with the *in vitro* interaction with the two isolated proteins. Finally, the most promising (most active, nontoxic, and BBB-permeable) compounds **22** and **23** were tested *in vivo*, in a *Drosophila melanogaster* model of AD. The carbazole derivative **22** (20 μ M) showed extremely encouraging results, being able to improve both the lifespan and the climbing abilities of A β_{42} expressing flies and generating a better outcome than doxycycline (50 μ M). Moreover, **22** proved to be able to decrease A β_{42} aggregates in the brains of the flies. We conclude that bivalent small molecules based on **22** deserve further attention as hits for dual A β /Tau aggregation inhibition in AD.

KEYWORDS: aggregation inhibitors, multitarget-directed ligands, bivalent ligands, β -amyloid, tau protein, protein aggregates



INTRODUCTION

Alzheimer's disease (AD) is the most common cause of dementia and one of the most important unmet medical needs worldwide. In 2020, over 50 million people were living with dementia globally, a figure set to increase to 152 million by 2050.¹ Importantly, the most alarming data is the lack of truly disease-modifying treatments in the clinic. Actually, the year 2021 set a milestone for the field, with the approval of aducanumab by the Food and Drug Administration (FDA)—the first new medication in 18 years. Aducanumab, which is a monoclonal antibody (mAb) targeting amyloid- β (A β), has been approved for the treatment of patients with mild to moderate AD. However, its approval remains controversial, due to ambiguous clinical results on its efficacy and the refusal of marketing authorization by the European Medicines Agency (EMA) in December 2021. Thus, even though its approval has raised hopes for AD patients, postapproval trials will be key to truly understand its clinical benefits.² Notably, two further anti-amyloid mAbs, lecanemab and donanemab, have been granted breakthrough therapy designation by the FDA.³


The aducanumab story, unfortunately, indicates that it is still difficult to translate promising preclinical data into clinical

efficacy.⁴ Probably, the removal of plaques *per se* is neither sufficient to clearly improve brain function and to boost cognition nor to delay AD progression in AD patients.⁵ A possible explanation is that a greater insight into the interrelationship between A β and Tau is needed to understand AD pathogenesis and explain the failure of previous therapeutic strategies.⁵ A β and Tau aggregates are well-defined pathological hallmarks and validated targets in AD, but how they interact has been largely unknown. There is accumulating evidence that A β and Tau proteins may act synergistically to cause synaptic dysfunction, neurofibrillary tangle-mediated neuronal loss, and behavioral deficits. A recent publication has shed light on how A β and Tau might cooperate in causing AD phenotypes.⁶ A β seems to initiate the neuroinflammation

Received: June 22, 2022

Accepted: November 17, 2022

Published: November 29, 2022






Figure 1. Examples of known palindromic antiaggregating compounds.




Figure 2. Design strategy and general structure of bivalent derivatives 1–24. Two 2,4-thiazolidinedione protein recognition motifs (PRMs) (25–28) were connected via an aromatic linker (a–f).


process, making synapses vulnerable to Tau-associated molecular changes, such as the loss of synaptic proteins. Thus, although Tau may be sufficient to induce neuroinflammation, A β plaques could induce inflammatory changes that exacerbate degeneration when Tau is present.⁶ Another recent seminal study has revealed how A β and Tau synergize to damage the functional integrity of neural circuits and provided a likely explanation for the disappointing results from anti-A β clinical trials.⁷

Based on this perspective, the development of multitarget-directed ligands (MTDLs)⁸ able to target both A β and Tau aggregation processes, might be an option to pursue.⁹

In recent years, few AD drug discovery programs have focused on dual A β /Tau inhibitors, able to interfere with protein–protein interactions (PPIs), to avoid propagation, or to prevent fibril formation. However, not many of these inhibitors were purposely designed to target A β and Tau

aggregation simultaneously; most of the reports focused on acetylcholinesterase (AChE) inhibitors where A β and Tau antiaggregation was an activity designed-in by random screening. Indeed, the rationale modulation of PPIs by small molecules has been considered quite challenging for several reasons: lack of druggable active sites or pockets; paucity of high-resolution structural information on amyloid aggregates; and multiple electrostatic, polar, and hydrophobic interactions across a large interface.¹⁰ To overcome these issues, knowledge-centric ligand-based strategies may be of help.

We noticed that several antiaggregating compounds share a symmetrical bifunctional structure, consisting of two identical amyloid protein recognition motifs (PRMs) joined by an appropriate spacer (Figure 1).¹¹ These symmetrical compounds have been described as bivalent compounds or “palindromic compounds”,¹² as their structure can be read in the same way in the forward or reverse direction. Considering

Scheme 1. Synthetic Procedure for the Synthesis of Target Compounds 1–24^a

^aReagents and Conditions: (a) EDDA, 100 °C, 45 min, MWI and (b) AcOH, HCl, 120 °C, 6 h.

the oligomeric and repetitive structure of fibrillar aggregates, bivalent compounds have been suggested to interact simultaneously with the two binding surfaces. Thus, bivalent ligands should cross-link fibrils and perturb the aggregation process.


In light of this, we focused on a bivalent strategy to identify novel MTDLs able to inhibit both A β and Tau aggregation processes. Herein, we describe the design and synthesis of a library of bivalent 2,4-thiazolidinedione (TZD, **25** in Figure 2) derivatives (**1–24**, general structure in Figure 2), together with the *in vitro*, *in cellulo*, and *in vivo* evaluation of their inhibitory activity against the aggregation of A β and Tau proteins.

RESULTS AND DISCUSSION


Design. The design strategy for bivalent compounds **1–24** is illustrated in Figure 2. The selection of the TZD moiety **25** as PRM was motivated by several observations. Thanks to the presence of two H-bond acceptor and one H-bond donor

groups, TZD and rhodanine scaffolds (5-arylidene substituted) have been shown by us and others to selectively recognize amyloid fibrillar structures and display promising antiaggregating properties.^{13,14} Interestingly, molecular dynamics simulations revealed critical interactions, which account for the tight binding of TZD to the Tau hexapeptide core fragment and allow disruption of the ordered structure of oligomers.¹⁵ Considering the role of electrostatic interactions within the architecture of amyloid fibrils,¹⁶ we decorated the TZD scaffold with different ionizable groups. Thus, a carboxylic acid and a secondary amine were selected as substituents for the nitrogen of the TZD scaffold (**27** and **28**). To study the impact of this functionalization on the antiaggregating activity, the corresponding nonionizable ester derivative **26** was also selected.

After the selection of the proper PRMs, we turned our attention to suitable linkers. Several antiaggregating bivalent compounds share a common chemical structure consisting of

Scheme 2. Synthetic Procedure for the Synthesis of *N*-Substituted TZD Derivatives 26 and 28^a

^aReagents and Conditions: (a) K₂CO₃, acetone, 100 °C, 45 min MWI and (b) Cs₂CO₃, acetone, 100 °C, 45 min MWI.

Scheme 3. Synthetic Procedure for the Synthesis of Dialdehydes 31–34^a

^aReagents and conditions: (a) formaldehyde, 33 wt % HBr in AcOH, reflux, 12 h; (b) HMTA, CHCl₃, reflux, 6 h; and (c) AcOH, reflux, 6 h; (d) nBuLi, DMF, THF dry, −78 °C to rt, 3 h.

planar, π -conjugated rings able to provide van der Waals and π - π stacking interactions.^{17,18} Thus, phenyl, biphenyl, diphenylmethane, carbazole, fluorene, and bisthiophene linkers were selected to evaluate the importance of the conjugation system for the antiaggregating activity of the bivalent compounds. Importantly, (bi)-phenyl,¹⁹ carbazole, and fluorene derivatives have been reported as inhibitors of A β aggregation,^{20,21} while bisthiophene and pentameric thiophene derivatives are well-known A β and Tau fluorescent probes.^{22–24} The combination of four different TZD-based PRMs with six different aromatic linkers, led to the development of a combinatorial library of 24 bivalent compounds (1–24, see Scheme 1 for individual structures).

Chemistry. Target compounds 1–24 were assembled by condensing dialdehyde linkers with two PRMs via an optimized version of the Knoevenagel reaction (Scheme 1).¹⁴ The procedure is green, catalyzed by ethylenediamine diacetate (EDDA) under solvent-free conditions and microwave irradiation (MWI) at 100 °C, for 45 min. In detail, the unsubstituted-(1–6), ethyl ester-(7–12), and *N*-dimethylamino-derivatives (19–24) were synthesized through the condensation of TZD derivatives 25, 26, and 28 (3 equiv) with aromatic dialdehydes 29–34 (1 equiv), in the presence of EDDA (0.5 equiv). The bivalent derivatives 1–12 and 19–24 were obtained with yields varying from 18 to 75%. For the synthesis of carboxyl-derivatives (13–18), the Knoevenagel

reaction was followed by acid-catalyzed hydrolysis of the corresponding ester derivatives (Scheme 1). Thus, esters 7–12 were refluxed in acetic acid and concentrated HCl overnight, yielding the carboxylic acids 13–18 in good yields (30–86%).

The synthesis of *N*-substituted TZD intermediates was also developed. Compound 26 was obtained in good yield (87%, Scheme 2) upon *N*-alkylation of 25 with ethyl-2-bromoacetate (35), under MWI, in acetone at 100 °C for 45 min. The *N*-alkylation protocol for the synthesis of 28 required the use of a stronger base, i.e., Cs₂CO₃ instead of K₂CO₃ (53% yield, Scheme 2).

While dialdehyde intermediates 29 and 30 were commercially available, dialdehydes 31–34 were synthesized, as reported in Scheme 3. Synthesis of 31 was achieved through a two-step sequence (Scheme 3).²⁵ In the first step, dibromomethylation of diphenylmethane 37 with formaldehyde and 33 wt % solution of HBr in acetic acid gave intermediate bis[4-(bromomethyl)phenyl]methane 38 (20%). The second step was a Sommelet reaction in which 38 was converted to 31, using hexamethylenetetramine (HMTA), with a moderate yield (42%).²⁶ The synthesis of dialdehydes 32–34 was achieved in moderate to good yields (45–58%) through direct lithiation of the corresponding dibromo derivatives 39–41 and subsequent formylation (Scheme 3).²⁷ To the best of our knowledge, this is the first case in which this

Table 1. Inhibitory Activity of Bivalent Derivatives 1–24 toward $A\beta_{42}$ and Tau Aggregation, Together with Neurotoxicity Data on Differentiated CGNs (24 h Treatment)

cmp	linker	R	% inhibition $A\beta_{42}$ aggregation @ 10 μM ^a	% inhibition Tau aggregation @ 10 μM ^a	% survival neurotoxicity @ 10 μM ^b
1	phenyl	-H	25.4 $\pm$ 1.9	19.4 $\pm$ 3.6	77.6 $\pm$ 6.1
2	biphenyl	-H	20.2 $\pm$ 2.1	16.5 $\pm$ 3.1	81.3 $\pm$ 6.5
3	diphenylmethane	-H	12.9 $\pm$ 3.4	5.2 $\pm$ 2.7	62.4 $\pm$ 9.6
4	carbazole	-H	24.7 $\pm$ 4.1	21.2 $\pm$ 2.6	73.4 $\pm$ 5.1
5	9,9-dimethylfluorene	-H	23.6 $\pm$ 2.6	14.8 $\pm$ 3.0	67.9 $\pm$ 5.4
6	bisthiophene	-H	42.4 $\pm$ 4.5	19.4 $\pm$ 3.9	89.9 $\pm$ 1.2
7	phenyl	-CH ₂ COOCH ₂ CH ₃	40.7 $\pm$ 4.4	30.6 $\pm$ 3.6	90.1 $\pm$ 2.1
8	biphenyl	-CH ₂ COOCH ₂ CH ₃	14.3 $\pm$ 3.5	18.1 $\pm$ 3.2	87.2 $\pm$ 3.1
9	diphenylmethane	-CH ₂ COOCH ₂ CH ₃	14.5 $\pm$ 4.1	19.9 $\pm$ 3.6	88.7 $\pm$ 4.1
10	carbazole	-CH ₂ COOCH ₂ CH ₃	31.9 $\pm$ 3.0	37.7 $\pm$ 4.1	84.2 $\pm$ 6.3
11	9,9-dimethylfluorene	-CH ₂ COOCH ₂ CH ₃	17.5 $\pm$ 4.5	33.1 $\pm$ 4.5	85.8 $\pm$ 6.9
12	bisthiophene	-CH ₂ COOCH ₂ CH ₃	7.0 $\pm$ 3.7	9.2 $\pm$ 5.0	90.2 $\pm$ 2.1
13	phenyl	-CH ₂ COOH	16.1 $\pm$ 3.9	25.3 $\pm$ 4.2	82.3 $\pm$ 2.9
14	biphenyl	-CH ₂ COOH	35.1 $\pm$ 1.9	27.1 $\pm$ 2.5	89.0 $\pm$ 2.2
15	diphenylmethane	-CH ₂ COOH	26.2 $\pm$ 1.9	3.8 $\pm$ 5.2	90.9 $\pm$ 1.5
16	carbazole	-CH ₂ COOH	32.1 $\pm$ 3.1	37.9 $\pm$ 3.5	90.0 $\pm$ 2.8
17	9,9-dimethylfluorene	-CH ₂ COOH	51.4 $\pm$ 2.7	55.6 $\pm$ 3.2	89.3 $\pm$ 2.3
18	bisthiophene	-CH ₂ COOH	65.6 $\pm$ 3.3	15.8 $\pm$ 4.7	90.9 $\pm$ 3.1
19	phenyl	-CH ₂ CH ₂ N(CH ₃) ₂	8.1 $\pm$ 4.4	19.4 $\pm$ 3.6	89.4 $\pm$ 2.0
20	biphenyl	-CH ₂ CH ₂ N(CH ₃) ₂	26.4 $\pm$ 4.2	34.9 $\pm$ 1.9	91.1 $\pm$ 0.9
21	diphenylmethane	-CH ₂ CH ₂ N(CH ₃) ₂	16.1 $\pm$ 3.8	38.7 $\pm$ 3.3	91.1 $\pm$ 1.5
22	carbazole	-CH ₂ CH ₂ N(CH ₃) ₂	74.0 $\pm$ 4.3	66.1 $\pm$ 3.9	94.3 $\pm$ 1.8
23	9,9-dimethylfluorene	-CH ₂ CH ₂ N(CH ₃) ₂	44.8 $\pm$ 4.7	41.9 $\pm$ 3.9	87.9 $\pm$ 3.4
24	bisthiophene	-CH ₂ CH ₂ N(CH ₃) ₂	20.3 $\pm$ 4.8	17.3 $\pm$ 4.5	88.8 $\pm$ 2.3
Huprine Y			4.6 $\pm$ 2.3	n.d.	n.d.
HUP7TH			77.6 $\pm$ 1.5	69.5 $\pm$ 1.6	n.d.
Rhein			n.d.	39.2 $\pm$ 2.1	n.d.

^aInhibition of $A\beta_{42}$ and Tau aggregation in intact *E. coli* cells upon treatment with a compound concentration of 10 μM . Values are expressed as the mean $\pm$ SEM of four independent experiments. ^bViability of cerebellar granule neurons (CGNs) after 24 h of incubation with the test compound at a 10 μM concentration. The results are expressed as a percentage of healthy nuclei on the total nuclei counting number, after Hoechst staining, and are the mean $\pm$ SEM of three different experiments; n.d. not determined.

reaction is exploited for the synthesis of 9,9-dimethylfluorene and bisthiophene dialdehydes.

All of the final compounds 1–24 were characterized in terms of identity and purity (¹H- and/or ¹³C NMR, LC-MS, HR-MS), and collected data are reported in the [Experimental Section](#) and [SI](#).

$A\beta_{42}$ and Tau Antiaggregating Activity. As it would have been labor-intensive and expensive to screen such a number of compounds in two separate antiaggregating studies using recombinant $A\beta$ and Tau, we turned our attention to a simple model of protein aggregation, namely, the intact *Escherichia coli* (*E. coli*) cells overexpressing $A\beta_{42}$ and Tau proteins.^{28,29} Building on the fact that inclusion bodies produced by overexpression of these proteins in *E. coli* mainly consist of fibrillar aggregates, this simple screening method uses bacteria as an *in vivo* reservoir for tracking the inhibition of amyloid-type protein aggregation in real time, using the amyloid dye thioflavin S (ThS). Of note, this screening has already been used for the evaluation of libraries of antiaggregating compounds.^{28–38}

All bivalent derivatives were tested at 10 μM concentration, and the obtained results are reported in [Table 1](#). Synthetic huprine Y (a poor inhibitor of $A\beta_{42}$ and Tau aggregation),³³ HUP7TH (a dual $A\beta_{42}$ /Tau inhibitor),³⁹ and natural anthraquinone rhein³³ were used as control compounds ([Figure S1](#)). Generally, derivatives featuring a phenyl, biphenyl, or diphenylmethane linker showed poor antiaggregating

activity, with percentages of inhibition lower than 30% for both proteins. Only the phenyl derivative 7 resulted moderately active, showing 40% inhibition for $A\beta_{42}$ aggregation and 30% for Tau. On the other side, carbazole and 9,9-dimethylfluorene derivatives showed more promising results. Carbazoles 10 and 16, carrying, respectively, an ester or a carboxylic acid appendage, showed moderate activity (% inhibition between 30 and 40%), while the *N,N*-dimethylaminoethyl derivative 22 resulted the most potent compound of the series. Compound 22 showed 74.0% inhibition of $A\beta_{42}$ aggregation and 66.1% inhibition of Tau aggregation. 9,9-dimethylfluorene derivatives 17 (acetic acid) and 23 (*N,N*-dimethylaminoethyl) showed an interesting activity on both aggregation processes, with % of inhibition higher than 50 and 40%, respectively.

Interestingly, a different behavior was observed for the bisthiophene derivatives. Indeed, while all the other analogues showed almost comparable activity in inhibiting the aggregation of both $A\beta_{42}$ and Tau proteins, bisthiophene derivatives showed selectivity toward $A\beta_{42}$ compared to Tau. This selectivity is exemplified by compounds 6 and 18. Indeed, both resulted poor inhibitors of Tau aggregation (inhibition < 20%), while showing interesting potency toward $A\beta_{42}$, with a remarkable 65.6% inhibition shown by 18.

Looking at the most active compounds (7, 10, 16–18, 22, and 23), it appears that the decoration of the PRM had an impact on the antiaggregating profile of these compounds.

Indeed, the addition of both ionizable (compare **16**–**18** vs **4**–**6**) and nonionizable (**7** vs **1**, **10** vs **4**) moieties on the TZD fragment led to more potent compounds. The most striking effect was for carbazole **22**, where the introduction of a protonatable group increased the activity from 24.7 and 21.2% (for unsubstituted **4**) to 74.0 and 66.1%, respectively. Of note, although the most potent compounds have two groups that should be mostly ionized at physiological pH, they are effectively internalized within *E. coli* cells. Thus, it might be anticipated that permeation across the two-membrane bacterial cell envelope, which might have reduced their effective concentrations in *E. coli* and, hence, their activities, should not be an issue for these compounds.

Toxicity in Cerebellar Granule Neurons. In parallel with the evaluation of the antiaggregating potential, we assessed the neurotoxicity of all bivalent derivatives (**1**–**24**) on rat primary cultures of cerebellar granule neurons (CGNs), by healthy vs total nuclei counting after Hoechst staining. In this way, we aimed to remove potentially toxic compounds from consideration early in the screening process. CGNs were established a few decades ago, and since then have become one of the most useful *in vitro* models to study neuronal death.⁴⁰ The compounds were tested at 10 μ M concentration after 24 h treatment, and results are reported in Table 1.

Generally, all of the compounds were well tolerated, with 17 analogues out of 24 showing cell viability higher than 85%. Interestingly, the only four compounds (**1**, **3**–**5**) showing some neurotoxic effect (cell viability < 80%), shared the unsubstituted TZD moiety. Thus, the addition of the appendage moiety on TZD seems favorable also in terms of potential neurotoxic effects.

Both the collected A β and Tau antiaggregating activities and neurotoxicity data were considered for compound progression. Particularly, requirements for further evaluation were (i) lack of neurotoxicity and (ii) inhibition of both A β and Tau aggregation higher than 30%. Thus, compounds **7**, **10**, **16**, **17**, **22**, and **23** progressed to the next assay.

Blood–Brain Barrier Permeability Prediction. One of the main problems in developing a CNS-active compound relies on the ability of such a compound to permeate the blood–brain barrier (BBB) at its therapeutic concentration. Thus, to reduce attrition in the development process, the evaluation of BBB penetration at a very early drug discovery stage is of crucial importance. In light of this, the ability of the previously selected compounds to cross the BBB was predicted by a parallel artificial membrane permeability assay (PAMPA)-BBB,⁴¹ a high-throughput technique widely used as an indicator of a molecule's passive diffusion through the BBB. Six commercially available drugs were used to validate the assay. A good correlation between reported and experimentally described values were obtained (see Supporting Information, Table S1). Thus, in accordance with data from the literature, compounds presenting an effective permeability (Pe) > 4.0×10^{-6} cm/s were classified as CNS permeable (CNS+). Based on this, the acetic acid derivatives **16** and **17** were classified as CNS-. However, as a very encouraging result, the ethyl esters **7** and **10**, and the dimethylamino analogues **22** and **23** were predicted to passively diffuse across the BBB. Notably, 9,9-dimethylfluorene **23** showed a Pe value similar to those of standard AD drugs donepezil and rivastigmine (Table S1).

Interaction with A β - and Tau-Isolated Proteins. After assessing the potential of the compounds to cross the BBB, we wanted to investigate the ability of the two most active and

BBB-permeable compounds, **22** and **23**, to interfere with the A β ₄₂ and Tau aggregation process *in vitro*, using isolated peptides and previously developed/validated aggregation assays.⁴² These assays allow us to indirectly monitor fibril formation, thanks to changes in the emission intensity of the fluorescent dye ThT when aggregates are formed.⁴² The achievement of reproducible and trustable data requires the final amount of organic solvents, and solubility issues are carefully prechecked.⁴³ Hence, to assess antiaggregation properties toward A β ₄₂, these aspects were investigated in dedicated solubility assays. The results showed that compound solubility in the assay condition was too limited to grant trustable results, thus preventing their evaluation on the commonly used ThT-based assay.

The interaction of a fluorescent compound with three-dimensionally organized A β ₄₂ fibrils may lead to a change in its fluorescent properties as a consequence of either a reduction of flexibility due to multiple-interaction points and/or of a change in compound–solvent interactions because of the insertion of the compound within fibril helices. Hence, a change in the spectral properties of a fluorescent compound potentially able to bind A β ₄₂ protofibrils/fibrils can be used as indirect proof that the two entities (amyloid and ligand) interact. This assay setup allows the use of a slightly higher amount of DMSO, which is sufficient to grant compound solubility, because addition of the tested compound to A β ₄₂ samples is performed when fibrillization has already occurred.

Thus, we recorded the emission spectra of compound **23** in the absence and presence of preaggregated A β ₄₂. While the excitation/emission maxima for the bound and unbound **23** did not significantly differ (i.e., $\lambda_{\text{exc}} = 374$ nm; λ_{em} maximum = 473 nm), a strong hyperchromic effect upon binding was observed, thus providing a proof of the interaction between the compound and the aggregated protein (Figure 3).




Figure 3. Fluorescence emission spectra of **23** (0.375 μ M) in Gly–NaOH buffer (50 mM, pH 8.5) in the absence (blue line) and presence (green line) of preaggregated A β ₄₂ (0.75 μ M). [A β ₄₂]/[**23**] = 2/1. $\lambda_{\text{exc}} = 374$ nm.

Secondly, we investigated the ability of the compounds to interfere with Tau aggregation, using the third repeat domain Tau fragment (Tau_(306–336) peptide).⁴⁴ The aggregation profiles of the Tau_(306–336) peptide (50 μ M) in the absence and presence of equimolar concentrations of either **22** or **23** were monitored in phosphate buffer 50 mM, pH 7.4, using Thioflavin T (ThT) as the detection dye. Unfortunately, under this experimental setup, solubility issues arose for

derivative **22**, which prevented us to obtain reliable trends. Conversely, compound **23** showed a strong antiaggregating activity ($51.8 \pm 11.7\%$ inhibition), resulting only slightly less potent than the known Tau inhibitor doxycycline ($61.5 \pm 0.8\%$ inhibition) (Figure 4 and Table S2).⁴⁵ Though, it was not able




Figure 4. Inhibition of Tau peptide_(306–336) aggregation (50 μ M) by compound **23** (50 μ M). Overlaid trends of the fluorescence intensity ($\lambda_{\text{exc}} = 446$ nm, $\lambda_{\text{em}} = 490$ nm) over 16-h incubation for the Tau peptide_(306–336) alone (black line) and in the presence of **23** (red line) in a 1/1 ratio. ThT was used as a fluorescent dye. Data are the mean of at least two independent experiments, each performed in duplicate.

to significantly delay the oligomerization phase (lag phases in the absence and presence of the inhibitor only slightly differ) and some dye displacement might contribute to some extent to a lower fluorescent signal.⁴⁵

Taken collectively, the data from *E. coli*, PAMPA, neurotoxicity, and aggregation assays were considered encouraging enough to further explore the potential of our bivalent compounds **22** and **23** in an *in vivo* AD model.

Activity Profile in a *Drosophila melanogaster* Model of AD. *Drosophila melanogaster* is a powerful *in vivo* model for the initial screening of AD drug candidates.^{46–49} In the last years, several transgenic flies expressing human $A\beta_{42}$ and Tau proteins have been developed, and they are now providing new insights into disease mechanisms, as well as assisting in the identification of novel AD drugs.^{50–55} Specifically, expression of the Arctic mutant (Glu22Gly) $A\beta_{42}$ in *Drosophila* neural tissue favors oligomer formation and results in different symptoms reminiscent of AD, including defective locomotion and memory, as well as markedly reduced longevity. Moreover,

fly brains display characteristic amyloid plaques and amyloid pathology.^{56–58} Based on the good correlation between $A\beta$ aggregation and the severity of the various AD phenotypes, we used Arctic $A\beta_{42}$ *Drosophila* flies to preliminarily test the effect of our bivalent derivatives **22** and **23**.

As longevity is a phenotype that can be rapidly measured in this *in vivo* AD model, we first assessed changes in *Drosophila*'s lifespan with and without treatment with **22** and **23** (20 μ M). We screened different concentrations, from 10 to 100 μ M, to assess the most effective dose. At the concentration of 20 μ M, we obtained the best results in combination with a low toxicity rate. We again used as control the antibiotic doxycycline, which is capable of halting amyloid aggregation of several disease-associated proteins (including $A\beta$ and Tau).⁴⁵ Doxycycline was tested at 50 μ M, a concentration used in similar previous experiments.⁵⁹ As shown in Figure 5A, after 20 days, only 50% of $A\beta_{42}$ flies were still alive. Importantly, treatment with both **22** and **23** resulted in an increase in longevity, being comparable to that of the reference compound doxycycline (at a higher concentration).

Locomotor effects in $A\beta_{42}$ *Drosophila* flies are clearly associated with $A\beta_{42}$ overexpression and in particular, climbing is a strong and reproducible behavior.⁵⁶ Thus, we performed behavioral tests to assess the climbing abilities of $A\beta_{42}$ *Drosophila* flies with and without treatment with **22** (20 μ M), **23** (20 μ M), and doxycycline (50 μ M), compared to control flies. As shown in Figure 5B, $A\beta_{42}$ *Drosophila* flies showed an important decline in their climbing ability compared to control flies, being almost immobile after day 21. Compound **23** showed a promising effect, with a partially recovered phenotype that lasted until day 14. Unfortunately, the effect was not sustained further, as there was no difference between the treated and untreated flies on day 21. On the other hand, treatment with **22** showed extremely promising results. Indeed, the positive effect of **22** was sustained for all of the different time points, greatly improving the climbing performances of $A\beta_{42}$ *Drosophila* flies. Importantly, **22** resulted to be even more active than doxycycline. On day 21, good climbing performances of flies treated with **22** persisted, while they strongly declined in doxycycline-treated flies. We should again remark that the testing concentration for **22** was lower (20 μ M) compared to doxycycline (50 μ M). Finally, data collected on *Drosophila* nicely reflected the antiaggregating




Figure 5. (A) Lifespan analysis comparing treated and untreated $A\beta_{42}$ *Drosophila* flies, together with w^{1118} flies as control (CTR flies), on days 5, 10, and 20 post-eclosion (* p -value < 0.05). (B) Behavioral test measuring the climbing abilities of treated and untreated $A\beta_{42}$ *Drosophila* flies, together with w^{1118} flies as control (CTR flies), on days 7, 14, and 21 post-eclosion. Values are expressed as the mean $\pm$ SEM. Unpaired t-test resulted statistically different (** p -value < 0.005; *** p -value < 0.001; and **** p -value < 0.0001 compared to $A\beta_{42}$ flies).




Figure 6. Immunofluorescence staining of $A\beta_{42}$ aggregates within flies' brains. (A) Untreated $A\beta_{42}$ *Drosophila* flies, showing $A\beta_{42}$ aggregates visible as green deposits. (B) Magnification of the selected area from A, showing $A\beta_{42}$ aggregates. (C) $A\beta_{42}$ *Drosophila* flies treated with **22** showed almost the absence of $A\beta_{42}$ aggregates. (D) Magnification of the selected area from C. Scale bar: 150 μm in panels (A) and (C); 50 μm in panels (B) and (D). (E) Quantification analysis of $A\beta_{42}$ accumulation in $A\beta_{42}$ *Drosophila* flies' brains ($n=8$ each genotype). Unpaired *t*-test comparing untreated and treated flies resulted statistically different (***) $p < 0.001$.

results obtained in *E. coli*, with carbazole **22** being more active than 9,9-dimethylfluorene **23**.

Motivated by these positive results, we decided to study the ability of the most promising **22** to reduce the presence of amyloid plaques and aggregates in the brain of $A\beta_{42}$ flies. Indeed, these flies are characterized by intracellular $A\beta_{42}$ accumulation, followed by non-amyloid aggregates that resemble diffuse plaques.⁵⁶ Thus, the brains of treated and untreated flies, together with the control, were dissected and analyzed at 15 days post-hatching. Confocal microscopy of untreated $A\beta_{42}$ *Drosophila* flies showed diffuse peptide aggregates distributed throughout the brain, especially within the *Drosophila* mushroom body (Figure 6A,B). Importantly, such deposits were nearly absent in the brains of $A\beta_{42}$ *Drosophila* flies treated with **22** (Figure 6C,D). Quantification analysis showed an 80% reduction of aggregates in $A\beta_{42}$ *Drosophila* adult brains treated with carbazole **22**, compared with untreated ones (Figure 6E). This result might confirm that the increased life span and locomotive ability were linked to a direct antiaggregating effect.

In addition, the observed *Drosophila* profile might be encouraging because after administration in the fly food, **22** is able to exert its effect on $A\beta_{42}$ expressed in the CNS of a whole organism.

CONCLUSIONS

The complex nature of AD, together with a still poor understanding of its pathophysiological mechanisms, seems to be responsible for the lack of effective treatments in the clinic. However, several studies are now shedding light on the interconnected role of two pathognomonic proteins in AD: $A\beta$ and Tau. Available evidence suggests these proteins can act synergistically, causing synaptic dysfunction, neuronal loss, and behavioral deficits. In light of this, we decided to apply an MTDL approach directed to both these protein aggregates in AD. We believe that the development of a dual $A\beta$ /Tau aggregation inhibitor should be more effective, compared to existing single-target treatments (e.g., aducanumab). Thus, we presented here the design and synthesis of a focused library of 24 bivalent TZD derivatives (**1–24**), aiming to inhibit both $A\beta_{42}$ and Tau protein aggregation. The most promising compound from this series is the carbazole derivative **22**, which showed positive antiaggregating results in intact *E. coli* cells overexpressing $A\beta_{42}$ and Tau proteins, no neurotoxicity in primary CGNs, and BBB permeability in a PAMPA–BBB assay. Moreover, compound **22** ameliorated AD-like phenotypes in a transgenic *Drosophila melanogaster* model of Alzheimer's disease/ $A\beta$ toxicity, being even more effective than the dual inhibitor doxycycline. Carbazole **22** was able not only to improve the lifespan and climbing abilities of $A\beta_{42}$ expressing flies but also to reduce the presence of amyloid aggregates in their brains. It is important to highlight, however,

that the poor solubility of compound **22** prevented us from studying in more depth its *in vitro* interaction with the isolated proteins.

In this respect, we cannot exclude that the mechanism of amyloid aggregation modulation by **22** may occur by its self-assembly into aggregates and consequent interactions with the aggregating protein^{60,61} in a manner characteristic of colloidal inhibition. This is a potential mechanism of many compounds inhibiting aggregation of diverse amyloid-type proteins.⁶⁰

In conclusion, this new class of dual antiaggregating compounds could represent a promising starting point for the design of the second generation of analogues, where improved solubility and elucidation of the molecular mechanism of action would be key needed steps to allow compounds to be progressed for further studies.

EXPERIMENTAL SECTION

Chemistry. All of the commercially available reagents and solvents were purchased from Sigma-Aldrich, Alpha Aesar, and VWR, and used without further purification. Reactions were followed by analytical thin-layer chromatography (TLC), on precoated TLC plates (layer 0.20 mm silica gel 60 with a fluorescent indicator UV254, from Sigma-Aldrich). Developed plates were air-dried and analyzed under a UV lamp (UV 254/365 nm). A CEM Discover SP-focused microwave reactor was used for microwave-mediated reactions. All melting points (m.p.) were determined in open glass capillary tubes using a BÜCHI Melting Point B-540 apparatus. Nuclear magnetic resonance (NMR) experiments were run on a Varian VXR 400 (400 MHz for ¹H, 100 MHz for ¹³C). ¹H and ¹³C NMR spectra were acquired at 300 K using deuterated dimethyl sulfoxide (DMSO-*d*₆), chloroform (CDCl₃), or trifluoroacetic acid (TFA-*d*₁) as solvents. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS) as the internal reference, and coupling constants (*J*) are reported in hertz (Hz). The spin multiplicities are reported as *s* (singlet), *br s* (broad singlet), *d* (doublet), *t* (triplet), *q* (quartet), and *m* (multiplet). Exchangeable NH or OH protons were not observed in the ¹H spectra of **1**, **3**, **15**, **17**, and **18**. Low-resolution and high-resolution mass spectra were recorded on a VG707EH-F or a Xevo G2-XS QToF apparatus, and electrospray ionization (ESI) both in positive and negative modes was applied. All the final compounds showed ≥95% purity by analytical HPLC. Compounds were named following IUPAC rules as applied by ChemBioDraw Ultra (version 14.0). As already reported,⁶² final compounds **1–24** were obtained as single *Z* isomers. Indeed, their ¹H NMR spectra show only one signal attributable to the resonance of the 5-methylidene proton in the range 7.50–8.70 ppm, while in their ¹³C NMR spectra the 5-methylidene carbon and the C5 of the TZD ring resonated in the ranges 130.5–140.7 and 117.5–128.0 ppm, respectively.

General Procedure for the Synthesis of Compounds **1–12 and **19–24**.** The corresponding dialdehydes (1 mmol) reacted with the corresponding TZD derivative (3 mmol), using EDDA (0.5 mmol) under microwave irradiation at 100 °C for 45 min. The reaction mixture was diluted with water and the solid was collected by filtration. After washing the solid with water, all of the final compounds were purified through crystallization or column chromatography. For compounds **1**, **6**, and **18** only ¹H NMR spectra were recorded, due to their extremely low solubility.

(5*Z*,5'*Z*)-5,5'-((1,4-Phenylenebis(methanylylidene))bis(thiazolidine-2,4-dione) (1**).** The title compound **1** was obtained as a yellow solid, according to the general procedure using **25** and dialdehyde **29**. Yield 75%. m.p. 236 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.79 (s, 2H); 7.72 (s, 4H). MS (ESI[−]) *m/z* for C₁₄H₈N₂O₄S₂: 331 [M − H][−]. HR-MS calcd for C₁₄H₇N₂O₄S₂ 330.9853, found 330.9860 [M − H][−].

(5*Z*,5'*Z*)-5,5'-((1,1'-Biphenyl)-4,4'-diylbis(methanylylidene))bis(thiazolidine-2,4-dione) (2**).** The title compound **2** was obtained as a yellow solid, according to the general procedure using **25** and dialdehyde **30**. Yield 57%. m.p. 249 °C (dec.); ¹H NMR (400 MHz,

DMSO-*d*₆): δ 12.63 (br s, 2H); 7.93 (d, *J* = 8.1, 4H); 7.84 (s, 2H); 7.71 (d, *J* = 8.1, 4H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.3; 168.0; 140.7; 133.3; 131.4; 131.2; 128.0; 124.5 (δ 162.73, 36.2, 31.2 residual DMF from recrystallization). MS (ESI[−]) *m/z* for C₂₀H₁₂N₂O₄S₂: 407 [M − H][−].

(5*Z*,5'*Z*)-5,5'-((Methylenebis(4,1-phenylene))bis(methanylylidene))bis(thiazolidine-2,4-dione) (3**).** The title compound **3** was obtained as a white solid, according to the general procedure using **25** and dialdehyde **31**. Yield 59%. m.p. 221 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.71 (s, 2H); 7.53 (d, *J* = 8.1, 4H); 7.40 (d, *J* = 8.1, 4H); 4.06 (s, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.9; 168.8; 143.6; 131.7; 131.3; 130.7; 130.1; 41.1; one carbon missing from the aromatic region. MS (ESI[−]) *m/z* for C₂₁H₁₄N₂O₄S₂: 421 [M − H][−].

(5*Z*,5'*Z*)-5,5'-((9*H*-Carbazole-3,6-diyl)bis(methanylylidene))bis(thiazolidine-2,4-dione) (4**).** The title compound **4** was obtained as a dark yellow solid, according to the general procedure using **25** and dialdehyde **32**. Yield 57%. m.p. 227 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.43 (br s, 2H); 12.07 (s, 1H); 8.48 (s, 2H); 7.97 (s, 2H); 7.68 (s, 4H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.8; 168.2; 141.8; 133.5; 128.8; 125.1; 124.2; 123.3; 120.5; 112.9. MS (ESI[−]) *m/z* for C₂₀H₁₁N₃O₄S₂: 420 [M − H][−].

(5*Z*,5'*Z*)-5,5'-((9,9-Dimethyl-9*H*-fluorene-2,7-diyl)bis(methanylylidene))bis(thiazolidine-2,4-dione) (5**).** The title compound **5** was obtained as a dark yellow solid, according to the general procedure using **25** and dialdehyde **33**. Yield 40%. m.p. 231 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.57 (br s, 2H); 8.06 (d, *J* = 8.0, 2H); 7.86 (s, 2H); 7.80 (s, 2H); 7.63 (dd, *J* = 8.0, 1.2, 2H); 1.51 (s, 6H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.5; 168.2; 155.3; 140.0; 133.6; 132.1; 129.9; 125.0; 124.1; 122.2; 47.2; 26.9. MS (ESI[−]) *m/z* for C₂₃H₁₆N₂O₄S₂: 447 [M − H][−].

(5*Z*,5'*Z*)-5,5'-((2,2'-Bithiophene)-5,5'-diylbis(methanylylidene))bis(thiazolidine-2,4-dione) (6**).** The title compound **6** was obtained as a red solid, according to the general procedure using **25** and dialdehyde **34**. Yield 25%. m.p. 260 °C (dec.); ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.62 (br s, 2H); 8.03 (s, 2H); 7.68 (s, 4H); (δ 7.95, 2.88, 2.73 residual DMF from recrystallization). MS (ESI[−]) *m/z* for C₁₆H₈N₂O₄S₄: 419 [M − H][−]. HR-MS calcd for C₁₆H₇N₂O₄S₄ 418.9294, found 418.9288 [M − H][−].

Diethyl 2,2'-((5*Z*,5'*Z*)-((1,4-phenylenebis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetate (7**).** The title compound **7** was obtained as a yellow solid, according to the general procedure using **26** and dialdehyde **29**. Yield 69%. m.p. 249 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.05 (s, 2H); 7.83 (s, 4H); 4.52 (s, 4H); 4.19 (q, *J* = 7.1, 4H); 1.22 (t, *J* = 7.1, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 166.8; 166.0; 165.3; 134.9; 132.7; 130.8; 123.2; 62.2; 42.2; 14.1. MS (ESI⁺) *m/z* for C₂₂H₂₀N₂O₈S₂: 527 [M + Na]⁺.

Diethyl 2,2'-((5*Z*,5'*Z*)-((1,1'-biphenyl)-4,4'-diylbis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetate (8**).** The title compound **8** was obtained as a yellow solid, according to the general procedure using **26** and dialdehyde **30**. Yield 30%. m.p. 288 °C (dec.); ¹H NMR (400 MHz, CDCl₃): δ 7.97 (s, 2H); 7.76 (d, *J* = 8.3, 4H); 7.63 (d, *J* = 8.3, 4H); 4.50 (s, 4H); 4.26 (q, *J* = 7.1, 4H); 1.31 (t, *J* = 7.1, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 167.2; 166.2; 165.5; 141.6; 133.7; 132.8; 130.9; 127.8; 121.4; 62.2; 42.2; 14.1. MS (ESI⁺) *m/z* for C₂₈H₂₄N₂O₈S₂: 603 [M + Na]⁺.

Diethyl 2,2'-((5*Z*,5'*Z*)-((methylenebis(4,1-phenylene))bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetate (9**).** The title compound **9** was obtained as a white solid, according to the general procedure using **26** and dialdehyde **31**. Yield 60%. m.p. 214 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.91 (s, 2H); 7.47 (d, *J* = 8.1, 4H); 7.31 (d, *J* = 8.1, 4H); 4.47 (s, 4H); 4.24 (q, *J* = 7.1, 4H); 4.08 (s, 2H); 1.30 (t, *J* = 7.1, 6H). ¹³C NMR (100 MHz, CDCl₃): δ 167.3; 166.2; 165.5; 143.2; 134.2; 131.4; 130.7; 129.8; 120.6; 62.1; 42.1; 41.7; 14.0. MS (ESI⁺) *m/z* for C₂₉H₂₆N₂O₈S₂: 617 [M + Na]⁺.

Diethyl 2,2'-((5*Z*,5'*Z*)-((9*H*-carbazole-3,6-diyl)bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetate (10**).** The title compound **10** was obtained as a yellow solid, according to the general procedure using **26** and dialdehyde **32**. Yield 37%. m.p. 246 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.08 (br s, 1H);

7.98 (s, 2H); 7.94 (s, 2H); 7.62–7.43 (m, 4H); 4.52 (s, 4H); 4.31 (q, J = 7.1, 4H); 1.35 (t, J = 7.1, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.5; 166.8; 165.6; 141.2; 135.4; 129.3; 125.5; 123.5; 123.2; 117.7; 112.0; 62.3; 42.1; 14.1. MS (ESI^+) m/z for $\text{C}_{28}\text{H}_{23}\text{N}_3\text{O}_8\text{S}_2$: 616 $[\text{M} + \text{Na}]^+$.

Diethyl 2,2'-((5Z,5'Z)-((9,9-dimethyl-9H-fluorene-2,7-diyl)bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))-diacetate (11). The title compound 11 was obtained as a yellow solid, according to the general procedure using 26 and dialdehyde 33. Yield 55%. m.p. 222 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.03 (s, 2H); 7.86 (d, J = 8.0, 2H); 7.60 (s, 2H); 7.55 (d, J = 8.0, 2H); 4.50 (s, 4H); 4.26 (q, J = 7.1, 4H); 1.56 (s, 6H); 1.31 (t, J = 7.1, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.3; 166.2; 165.5; 155.2; 140.5; 134.6; 133.2; 130.0; 124.6; 121.5; 120.7; 62.1; 47.1; 42.2; 26.9; 14.1. MS (ESI^+) m/z for $\text{C}_{31}\text{H}_{28}\text{N}_2\text{O}_8\text{S}_2$: 643 $[\text{M} + \text{Na}]^+$.

Diethyl 2,2'-((5Z,5'Z)-((2,2'-bithiophene)-5,5'-diylbis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))-diacetate (12). The title compound 12 was obtained as a red solid, according to the general procedure using 26 and dialdehyde 34. Yield 24%. m.p. 271 °C (dec.); ^1H NMR (400 MHz, $\text{CDCl}_3/\text{TFA}-d_1$): δ 8.12 (s, 2H); 7.43–7.40 (m, 4H); 4.53 (s, 4H); 4.28 (q, J_1 = 8 Hz, J_2 = 16 Hz, 4H); 1.30 (t, J_1 = 4 Hz, 4H). ^{13}C NMR (100 MHz, $\text{CDCl}_3/\text{TFA}-d_1$): δ 160.83, 160.40, 126.67, 118.41, 112.76, 109.93, 63.15, 42.49, 13.83. MS (ESI^+) m/z for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_8\text{S}_4$: 615 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((1,4-Phenylenebis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (19). The title compound 19 was obtained as a pale yellow solid, according to the general procedure using 28 and dialdehyde 29. Yield 27%. m.p. 218 °C (dec.); ^1H NMR (400 MHz, CDCl_3): δ 7.87 (s, 2H); 7.59 (s, 4H); 3.88 (t, J = 6.5, 4H); 2.58 (t, J = 6.5, 4H); 2.28 (s, 12H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.3; 166.1; 134.9; 131.9; 130.7; 123.6; 56.2; 45.5; 39.9. MS (ESI^+) m/z for $\text{C}_{22}\text{H}_{26}\text{N}_4\text{O}_4\text{S}_2$: 497 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((1,1'-Biphenyl)-4,4'-diylbis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (20). The title compound 20 was obtained as a yellow solid, according to the general procedure using 28 and dialdehyde 30. Yield 21%. m.p. 231 °C (dec.); ^1H NMR (400 MHz, CDCl_3): δ 7.92 (s, 2H); 7.73 (d, J = 8.3, 4H); 7.60 (d, J = 8.4, 4H); 3.88 (t, J = 6.5, 4H); 2.59 (t, J = 6.5, 4H); 2.29 (s, 12H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.7; 166.3; 141.4; 133.0; 132.8; 130.8; 127.7; 122.0; 56.3; 45.5; 39.9. MS (ESI^+) m/z for $\text{C}_{28}\text{H}_{30}\text{N}_4\text{O}_4\text{S}_2$: 573 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((Methylenebis(4,1-phenylene))bis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (21). The title compound 21 was obtained as a pale yellow solid, according to the general procedure using 28 and dialdehyde 31. Yield 20%. m.p. 168 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.86 (s, 2H); 7.45 (d, J = 8.0, 4H); 7.28 (d, J = 8.0, 4H); 4.06 (s, 2H); 3.87 (t, J = 6.4, 4H); 2.59 (t, J = 6.4, 4H); 2.29 (s, 12H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.8; 166.4; 142.9; 133.3; 131.6; 130.6; 129.8; 121.2; 56.2; 45.4; 41.7; 39.7. MS (ESI^+) m/z for $\text{C}_{29}\text{H}_{32}\text{N}_4\text{O}_4\text{S}_2$: 587 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((9H-Carbazole-3,6-diyl)bis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (22). The title compound 22 was obtained as a yellow solid, according to the general procedure using 28 and dialdehyde 32. Yield 18%. m.p. 220 °C (dec.); ^1H NMR (400 MHz, CDCl_3): δ 10.80 (s, 1H); 7.77 (s, 2H); 7.68 (s, 2H); 7.41 (m, 4H); 3.94 (s, 4H); 2.78 (s, 4H); 2.45 (s, 12H). ^{13}C NMR (100 MHz, CDCl_3): δ 168.0; 166.3; 141.8; 134.4; 129.7; 124.7; 123.4; 122.1; 116.9; 111.8; 56.4; 45.3; 39.2. MS (ESI^+) m/z for $\text{C}_{28}\text{H}_{29}\text{N}_5\text{O}_4\text{S}_2$: 586 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((9,9-Dimethyl-9H-fluorene-2,7-diyl)bis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (23). The title compound 23 was obtained as a dark yellow solid, according to the general procedure using 28 and dialdehyde 33. Yield 21%. m.p. 199 °C (dec.); ^1H NMR (400 MHz, CDCl_3): δ 7.96 (s, 2H); 7.81 (d, J = 8.0, 2H); 7.56 (s, 2H); 7.51 (d, J = 8.0, 2H); 3.87 (t, J = 6.4, 4H); 2.59 (t, J = 6.4, 4H); 2.28 (s, 12H); 1.52 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.81, 166.34, 155.14, 140.32, 133.78, 133.35, 129.94, 124.46, 121.36, 56.19, 47.08, 45.39, 29.67, 26.90. MS (ESI^+) m/z for $\text{C}_{31}\text{H}_{34}\text{N}_4\text{O}_4\text{S}_2$: 613 $[\text{M} + \text{Na}]^+$.

(5Z,5'Z)-5,5'-((2,2'-Bithiophene)-5,5'-diylbis(methanylylidene))bis(3-(2-(dimethylamino)ethyl)thiazolidine-2,4-dione) (24). The title compound 24 was obtained as a red solid, according to the general procedure using 28 and dialdehyde 34. Yield 25%. m.p. 247 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.20 (s, 2H); 7.73 (d, J = 4.0, 2H); 7.68 (d, J = 4.0, 2H); 4.01 (t, J = 5.6, 4H); 3.40 (t, J = 5.6, 4H); 2.87 (s, 12H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6/\text{TFA}-d_1$): δ 167.1; 165.8; 142.1; 137.7; 136.9; 127.6; 126.1; 119.9; 54.3; 42.7; 37.3. MS (ESI^+) m/z for $\text{C}_{24}\text{H}_{26}\text{N}_4\text{O}_4\text{S}_4$: 585 $[\text{M} + \text{Na}]^+$.

General Procedure for the Synthesis of Compounds 13–18. The corresponding ester derivatives (0.1 mmol) were refluxed overnight in acetic acid (4 mL) and concentrated HCl (1 mL). The reaction mixture was filtered and the solid was washed three times with water, methanol, and dichloromethane (DCM) to give the final compounds.

2,2'-((5Z,5'Z)-((1,4-Phenylenebis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (13). The title compound 13 was obtained as a pale yellow solid, according to the general procedure using 7. Yield 86%. m.p. 251 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 13.48 (br s, 2H); 8.04 (s, 2H); 7.83 (s, 4H); 4.40 (s, 4H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.3; 167.1; 165.4; 135.0; 132.9; 131.34; 123.0; 42.9. MS (ESI^-) m/z for $\text{C}_{18}\text{H}_{12}\text{N}_2\text{O}_8\text{S}_2$: 447 $[\text{M} - \text{H}]^-$.

2,2'-((5Z,5'Z)-((1,1'-Biphenyl)-4,4'-diylbis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (14). The title compound 14 was obtained as a yellow solid, according to the general procedure using 8. Yield 50%. m.p. 302 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 13.42 (br s, 2H); 8.06 (s, 2H); 7.98 (d, J = 8.1, 4H); 7.79 (d, J = 8.1, 4H); 4.40 (s, 4H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.4; 167.2; 165.4; 141.1; 133.7; 133.0; 131.5; 128.1; 121.4; 42.8. MS (ESI^-) m/z for $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_8\text{S}_2$: 523 $[\text{M} - \text{H}]^-$.

2,2'-((5Z,5'Z)-((Methylenebis(4,1-phenylene))bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (15). The title compound 15 was obtained as a white solid, according to the general procedure using 9. Yield 33%. m.p. 277 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.96 (s, 2H); 7.60 (d, J = 8.2, 4H); 7.45 (d, J = 8.2, 4H); 4.37 (s, 4H); 4.09 (s, 2H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.4; 167.3; 165.5; 144.3; 134.1; 131.3; 131.0; 130.3; 120.5; 42.7; 41.1. MS (ESI^-) m/z for $\text{C}_{25}\text{H}_{18}\text{N}_2\text{O}_8\text{S}_2$: 537 $[\text{M} - \text{H}]^-$.

2,2'-((5Z,5'Z)-((9H-Carbazole-3,6-diyl)bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (16). The title compound 16 was obtained as a yellow solid, according to the general procedure using 10. Yield 50%. m.p. 285 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 13.43 (br s, 2H); 12.17 (s, 1H); 8.55 (s, 2H); 8.16 (s, 2H); 7.75–7.79 (m, 4H); 4.40 (s, 4H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.5; 167.6; 165.7; 142.1; 135.6; 129.0; 124.9; 124.7; 123.4; 117.3; 113.1; 42.7. MS (ESI^-) m/z for $\text{C}_{24}\text{H}_{15}\text{N}_3\text{O}_8\text{S}_2$: 536 $[\text{M} - \text{H}]^-$.

2,2'-((5Z,5'Z)-((9,9-Dimethyl-9H-fluorene-2,7-diyl)bis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (17). The title compound 17 was obtained as a yellow solid, according to the general procedure using 11. Yield 58%. m.p. 306 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.11 (d, J = 8.0, 2H); 8.08 (s, 2H); 7.88 (s, 2H); 7.69 (d, J = 8.0, 2H); 4.41 (s, 4H); 1.53 (s, 6H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.4; 167.3; 165.5; 155.4; 140.4; 134.4; 133.4; 130.1; 125.4; 122.5; 120.9; 47.3; 42.8; 26.8. MS (ESI^-) m/z for $\text{C}_{27}\text{H}_{20}\text{N}_2\text{O}_8\text{S}_2$: 563 $[\text{M} - \text{H}]^-$.

2,2'-((5Z,5'Z)-((2,2'-Bithiophene)-5,5'-diylbis(methanylylidene))bis(2,4-dioxothiazolidin-3-yl-5-ylidene))diacetic acid (18). The title compound 18 was obtained as a red solid, according to the general procedure using 12. Yield 30%. m.p. 339 °C (dec.); ^1H NMR (400 MHz, $\text{DMSO}-d_6/\text{TFA}-d_1$): δ 8.16 (s, 2H); 7.66 (d, J = 4.0, 2H); 7.61 (d, J = 4.0, 2H); 4.34 (s, 4H). MS (ESI^+) m/z for $\text{C}_{20}\text{H}_{12}\text{N}_2\text{O}_8\text{S}_4$: 559 $[\text{M} + \text{Na}]^+$. HR-MS calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_8\text{S}_4$ 534.9404, found 534.9402 $[\text{M} - \text{H}]^-$.

Ethyl 2-(2,4-dioxothiazolidin-3-yl)acetate (26). A mixture of 25 (2 mmol), 35 (2 mmol), and anhydrous K_2CO_3 (3 mmol) in acetone (12 mL) was reacted under microwave irradiation at 100 °C for 45 min. After the reaction, the solid was removed by filtration, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography eluting with DCM/ethyl

acetate (9.6:0.4). Yield 87%. ^1H NMR (401 MHz, CDCl_3): δ 4.24 (s, 2H); 4.13 (q, J = 7.2, 2H); 3.97 (s, 2H); 1.20 (t, J = 7.2, 3H).

3-(2-(Dimethylamino)ethyl)thiazolidine-2,4-dione (28). A mixture of **25** (2 mmol), **36** (2 mmol), and Cs_2CO_3 (2 mmol) in acetone (12 mL) was reacted under microwave irradiation at 100 °C for 45 min. After the reaction, the solid was removed by filtration, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography eluting with DCM/ethanol/aqueous NH_4^+OH^- (9.5:0.5:0.05). Yield 53%. ^1H NMR (401 MHz, CDCl_3): δ 4.87 (s, 2H); 3.89 (s, 2H); 3.65 (t, J = 6.5, 2H); 2.42 (t, J = 6.5, 2H); 2.17 (s, 6H).

4,4'-Methylenedibenzaldehyde (31). Compound **37** (12 mmol) and paraformaldehyde (42 mmol) were dissolved in 8 mL of glacial acetic acid containing 33 wt % HBr. After being refluxed for 12 h, the reaction flask was immersed in an ice bath. The white greasy solid was separated by decantation and washed three times with water. Recrystallization from toluene afforded bis(4-(bromomethyl)phenyl)methane **38** (yield 20%). ^1H NMR (401 MHz, CDCl_3): δ 7.32 (d, J = 8.0, 4H); 7.15 (d, J = 8.0, 4H); 4.48 (s, 4H); 3.96 (s, 2H). Hexamethylenetetramine (6 mmol) and bis(4-(bromomethyl)phenyl)methane (2 mmol) were separately dissolved into 4 mL of chloroform. The two solutions were mixed and refluxed for 6 h. The white precipitate was filtered and dried in vacuum overnight. Then, it was dissolved in 7 mL of 50% acetic acid and refluxed for 6 h; 1 mL of concentrated HCl was added and refluxed for another 2 h. The reaction solution was extracted with ethyl ether and then washed with 5N NaOH. The concentration of the ether portion and recrystallization from ethanol give **27** as a white solid. Yield 42%. ^1H NMR (401 MHz, CDCl_3): δ 9.99 (s, 2H); 7.83 (d, J = 8.0, 4H); 7.35 (d, J = 8.0, 4H); 4.14 (s, 2H).

General Procedure for the Synthesis of Dialdehydes 32–34. The corresponding starting dibromo derivatives (3 mmol) were dissolved in anhydrous THF (20 mL) and the solution was stirred in a dry ice/acetone bath; 8.5 mL of BuLi (2.5 M in hexane) was slowly added. The cooling bath was removed for 1 h and then placed again. After 10 min, anhydrous DMF (2.5 mL) was added dropwise. The cooling bath was removed, and the reaction was stirred for 90 min. After this period, 1M HCl (20 mL) was added, and the reaction was extracted twice with ethyl acetate. The combined extract was washed with brine, dried over Na_2SO_4 , and concentrated. The final compounds were purified through column chromatography.

9H-Carbazole-3,6-dicarbaldehyde (32). The title compound **32** was obtained as a yellow solid, according to the general procedure using **39**. Column chromatography eluted with DCM/ethyl acetate/toluene 6:3:1. Yield 58%. ^1H NMR (401 MHz, $\text{DMSO}-d_6$): δ 12.35 (br s, 1H); 10.09 (s, 2H); 8.88 (d, J = 1.2, 2H); 8.02 (dd, J = 8.5, 1.2, 2H); 7.72 (d, J = 8.5, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$): δ 192.4; 144.7; 129.6; 127.6; 125.2; 123.1; 112.6.

9,9-Dimethyl-9H-fluorene-2,7-dicarbaldehyde (33). The title compound **33** was obtained as a yellow solid, according to the general procedure using **40**. Column chromatography eluted with DCM. Yield 45%. ^1H NMR (401 MHz, CDCl_3): δ 10.06 (s, 2H); 7.99 (s, 2H); 7.96–7.82 (m, 4H); 1.53 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3): δ 191.9; 155.5; 143.7; 136.6; 130.3; 123.3; 121.6; 47.1; 26.7.

[2,2'-Bithiophene]-5,5'-dicarbaldehyde (34). The title compound **34** was obtained as a dark yellow solid, according to the general procedure using **41**. Column chromatography eluted with DCM/petroleum ether/toluene/ethyl acetate 5:3:1.5:0.5. Yield 57%. ^1H NMR (401 MHz, CDCl_3): δ 9.91 (s, 2H); 7.72 (d, J = 4.0, 2H); 7.42 (d, J = 4.0, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 182.5; 144.8; 143.8; 136.9; 126.4.

$\text{A}\beta_{42}$ and Tau Antiaggregating Activity. **Cloning and Overexpression of the $\text{A}\beta_{42}$ Peptide.** *Escherichia coli* competent cells BL21 (DE3) were transformed with the pET28a vector (Novagen, Inc., Madison, WI) carrying the DNA sequence of $\text{A}\beta_{42}$. Because of the addition of the initiation codon ATG in front of both genes, the overexpressed peptide contains an additional methionine residue at its N terminus. For overnight culture preparation, an amount of 10 mL of M9 minimal medium containing 50 $\mu\text{g}\cdot\text{mL}^{-1}$ kanamycin was inoculated with a colony of BL21 (DE3) bearing the

plasmid to be expressed at 37 °C. For expression of the $\text{A}\beta_{42}$ peptide, the required volume of overnight culture to obtain 1:500 dilution was added into fresh M9 minimal medium containing 50 $\mu\text{g}\cdot\text{mL}^{-1}$ kanamycin and 250 μM ThS. The bacterial culture was grown at 37 °C and 250 rpm. When the cell density reached $\text{ABS}_{600\text{ nm}} = 0.6$, an amount of 980 μL of culture was transferred into Eppendorf tubes of 1.5 mL with 10 μL of each compound to be tested in DMSO and 10 μL of isopropyl 1-thio- β -D-galactopyranoside (IPTG) at 100 mM. The final concentration of the drug was fixed at 10 μM . The samples were grown overnight at 37 °C and 1400 rpm using a thermomixer (Eppendorf, Hamburg, Germany). As the control of the amyloid presence (maximal amyloid presence), the same amount of DMSO without the drug was added to the sample. In parallel, noninduced samples (in the absence of IPTG) were also prepared and used as controls of the non-amyloid presence. In addition, the absorbance at 600 nm of the samples was checked to assess the potential intrinsic toxicity of the compounds and to confirm the correct bacterial growth.

Cloning and Overexpression of Tau Protein. *E. coli* BL21 (DE3) competent cells were transformed with pTARA containing the RNA-polymerase gen of the T7 phage (T7RP) under the control of the promoter PBAD. *E. coli* BL21 (DE3) with pTARA competent cells were transformed with the pRKT42 vector encoding four repeats of Tau protein in two inserts. For overnight culture preparation, 10 mL of M9 medium containing 0.5% of glucose, 100 $\mu\text{g}\cdot\text{mL}^{-1}$ ampicillin, and 12.5 $\mu\text{g}\cdot\text{mL}^{-1}$ chloramphenicol were inoculated with a colony of BL21 (DE3) bearing the plasmids to be expressed at 37 °C. For expression of Tau protein, the required volume of overnight culture to obtain 1:500 dilution was added to fresh M9 minimal medium containing 0.5% of glucose, 50 $\mu\text{g}\cdot\text{mL}^{-1}$ ampicillin, 12.5 $\mu\text{g}\cdot\text{mL}^{-1}$ chloramphenicol, and 25 μM ThS. The bacterial culture was grown at 37 °C and 250 rpm. When the cell density reached $\text{ABS}_{600\text{ nm}} = 0.6$, an amount of 980 μL of culture was transferred into Eppendorf tubes of 1.5 mL with 10 μL of each compound to be tested in DMSO and 10 μL of arabinose at 25%. The final concentration of the drug was fixed at 10 μM . The samples were grown overnight at 37 °C and 1400 rpm using a thermomixer (Eppendorf, Hamburg, Germany). As the control of maximal amyloid presence, the same amount of DMSO without the drug was added to the sample. In parallel, noninduced samples (in the absence of arabinose) were also prepared and used as controls for the amyloid absence. In addition, the absorbance at 600 nm of the samples was checked to assess the potential intrinsic toxicity of the compounds and to confirm the correct bacterial growth.

ThS Steady-State Fluorescence. ThS (T1892) and other chemical reagents were purchased from Sigma (St. Louis, MO). ThS stock solution (25 mM) was prepared in double-distilled water purified through a Milli-Q system (Millipore). For the fluorescence assay, the ThS spectra were measured on an AMINCO-Bowman series 2 luminescence spectrophotometer (Aminco-Bowman AB2, SLM Aminco, Rochester, NY) from 460 to 600 nm at 25 °C using an excitation wavelength of 440 nm and slit widths of 4 nm. The emission at 485 nm (fluorescence peak of ThS in the presence of amyloids) was recorded. To normalize the ThS fluorescence as a function of the bacterial concentration, $\text{ABS}_{600\text{ nm}}$ was obtained using a Shimadzu UV-2401 PC UV-Vis spectrophotometer (Shimadzu, Japan). Note that the fluorescence normalization was carried out considering as 100% the ThS fluorescence of the bacterial cells expressing the peptide or protein in the absence of the drug and 0% the ThS fluorescence of the bacterial cells nonexpressing the peptide or protein.

Neurotoxicity Evaluation on Primary Cultures of Cerebellar Granule Neurons. Primary cultures of CGNs were prepared from 7-day-old pups of Wistar rats (*Rattus norvegicus*). All animal experiments were authorized by the University of Bologna Bioethical Committee (Protocol no. 1088; Code 2DBFE.N.BFY) and performed according to Italian and European Community laws on the use of animals for experimental purposes. For cerebellar granule cultures, cells were dissociated from cerebella and plated on 35 mm $\varnothing$ dishes, previously coated with 10 $\mu\text{g}/\text{mL}$ poly-L-lysine, at a density of 1.2×10^6 cells/2

mL of medium BME supplemented with 100 mL/L heat-inactivated FBS (Life Technologies), 2 mmol/L glutamine, 100 μ M/L gentamicin sulfate, and 25 mmol/L KCl (all from Sigma-Aldrich); 16 h later, 10 μ M cytosine arabinofuranoside (Sigma-Aldrich) was added to avoid glial proliferation. After 7 days *in vitro*, differentiated neurons were shifted to serum-free BME medium containing 25 mmol/L KCl without the serum and different treatments were performed. For neurotoxicity experiments, differentiated CGNs were exposed to 10 μ M concentration of the studied compounds for 24 h in serum-free BME (25 mM KCl). The experiment was performed in triplicate. Since the native fluorescence of the library could interfere with the reading of the classical MTT cell viability assay, the Hoechst 33258 staining was performed to count healthy and apoptotic nuclei.

Nuclei Counting after Hoechst Staining. For nuclei counting after 24 h treatment, CGNs were fixed for 20 min with 4% PFA in phosphate buffer, washed in PBS, and incubated with 0.1 μ g/mL of Hoechst 33258 (Sigma-Aldrich) for 5 min at room temperature. After Hoechst staining, four randomly selected fields were acquired from each condition with a fluorescence microscope (20 $\times$ objective; Eclipse Hoechst staining TE 2000-S microscope, Nikon equipped with an AxioCam MRm (Zeiss, Oberkochen, Germany) digital camera. Neuronal survival was expressed as the percentage of healthy nuclei on the total nuclei number (mean $\pm$ SD) (Table 1).

PAMPA–BBB Assay. PAMPA (the parallel artificial membrane permeability assay) is a high-throughput screening tool applicable for the prediction of the passive transport of potential drugs across the BBB.⁴¹ In this study, it has been used as a non-cell-based *in vitro* assay carried out in a coated 96-well membrane filter. The filter membrane of the donor plate was coated with PBL (Polar Brain Lipid, Avanti) in dodecane (4 μ L of 20 mg/mL PBL in dodecane) and the acceptor well was filled with 300 μ L of phosphate buffer saline, (PBS pH 7.4; V_A). The tested compounds were dissolved first in DMSO and then diluted with PBS pH 7.4 to reach the final concentrations of 50–500 μ M in the donor well. The final concentration of DMSO did not exceed 0.5% (v/v) in the donor solution. Then, 300 μ L of the donor solution (V_D) was added to the donor wells and the donor filter plate was carefully put on the acceptor plate so that the coated membrane was “in touch” with both donor solution and acceptor buffer. In principle, the test compound diffuses from the donor well through the polar brain lipid membrane (area = 0.28 cm²) to the acceptor well. The concentrations of the tested compound in both donor and the acceptor wells were assessed after 3, 4, 5, and 6 h of incubation in quadruplicate using a UV plate reader, Synergy HT (Biotek) at the maximum absorption wavelength of each compound (n=3). In addition to that, solution of the theoretical compound concentration, simulating the equilibrium state established if the membrane were ideally permeable, was prepared and assessed as well. The concentrations of the compounds in the donor and acceptor wells and the equilibrium concentration were calculated from the standard curve and expressed as the permeability (Pe) according to the equation⁴¹

$$\log Pe = \log \left\{ C \times -\ln \left(1 - \frac{[\text{drug}]_{\text{acceptor}}}{[\text{drug}]_{\text{equilibrium}}} \right) \right\}$$

where

$$C = \left(\frac{V_D \times V_A}{(V_D + V_A) \times \text{area} \times \text{time}} \right)$$

Evaluation of Optical Properties of 23 in the Presence of Aggregated A β 42. As reported in a previously published protocol,⁴² 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)-pretreated A β 42 samples (Bachem AG, Switzerland) were solubilized with a CH₃CN/0.3 mM Na₂CO₃/250 mM NaOH (48.4:48.4:3.2) mixture to obtain a 500 μ M solution. Aggregation was achieved by diluting the peptide to a final concentration of 50 μ M with 10 mM phosphate buffer (pH = 8.0) containing 10 mM NaCl and incubating the diluted solution at 30 $^{\circ}$ C for 24 h. This protocol was previously shown to give a reproducible aggregation kinetics.⁴²

A 1.5 mM stock solution of 23 in methanol was prepared and diluted in 50 mM glycine–NaOH buffer (pH 8.5) to a final concentration of 0.375 μ M. Excitation and emission fluorescence spectra in the absence and in the presence of preaggregated A β 42 (0.75 μ M) were recorded using the following instrument setup: λ_{exc} = 374 nm, emission range = 400–600 nm; λ_{em} = 473 nm; excitation range = 250–460 nm; bandwidth (Ex) = 5 nm; bandwidth (Em) = 5 nm; scanning speed = 500 nm.

Inhibition of Tau_(306–336) Peptide Aggregation. Briefly, 1 mg of Tau_(306–336) (Bachem AG, Germany) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), gently vortexed, sonicated, and kept overnight at room temperature. Subsequently, the sample was aliquoted, dried, and stored at -20° C. Stock solutions of Tau_(306–336) peptide (500 μ M) were prepared in ultrapure water and immediately used. Stock solution of Thioflavin T (ThT, 500 μ M) was prepared in 56.3 mM phosphate buffer (PB, pH = 7.4), while stock solutions of inhibitors (20 mM) and of the reference compound doxycycline (10 mM) were prepared in DMSO/methanol 10/90. Tau_(306–336) aggregation was monitored at 30 $^{\circ}$ C in a black, clear bottom 96-well plate (Greiner) by the EnSpire multiplate reader (Perkin Elmer) using the ThT fluorimetric assay¹⁴ with some variations. The excitation and emission wavelengths were set at 446 and 490 nm, respectively. Assay samples were prepared by diluting Tau_(306–336) stock solution to 50 μ M in the assay mixture which consisted of 20 μ M ThT, 48.1 mM PB (final concentrations) in the final 100 μ L volume (final DMSO and MeOH contents: 0.05 and 0.45%, respectively). Inhibition experiments were performed by incubating Tau_(306–336) peptide in the given conditions in the presence of tested inhibitors at 50 μ M. Fluorescence data were recorded every 10 min overnight with 1 min shaking at 800 rpm prior to each reading. Each inhibitor was assayed in triplicate in at least two independent experiments. Estimation of the inhibitory potency (%) was carried out by comparing fluorescence values at the plateau (average fluorescence intensity value in the 12–16 h range). Inhibition % is expressed as the mean $\pm$ SEM. Quenching of ThT fluorescence was evaluated by preparing blank solutions containing the inhibitor/reference compound and preformed fibrils of Tau_(306–336) peptide.

Drosophila Melanogaster Model of AD. Flies w¹¹¹⁸ (control flies indicated as CTR) and Elav > Gal4;UAS-ArcticA β 42 (experimental population) were maintained at 25 $^{\circ}$ C and flipped into new vials every 2 days. The experimental flies take advantage of the UAS-Gal4 binary system, where these two are not found in the fly genome, and thus their introduction permits extremely specific control of the transgene expression.⁶³ The transactivating protein GAL4 is placed under the control of a specific promoter, with its own spatial and temporal patterns, in this case, Elav, whereas the upstream activation sequence (UAS) localized upstream, the locus controlled by the UAS-Gal4; in our study, UAS expresses construct for the E22G variant of A β 42 (Arctic A β 42) (AlzArc2).^{56,64} Around 150 flies (half female/male) for each compound tested were collected and divided into groups of 25 flies. At the top of the media, 25 μ L of doxycycline (50 μ M), 22 (20 μ M), or 23 (20 μ M) were added fresh anytime the flies were flipped.

Climbing Assay and the Survival Rate. The behavioral assays follow the protocol illustrated in Albertini et al.⁵⁹ Briefly, males and females 25 per vial were kept at 25 $^{\circ}$ C. The climbing test was performed on days 7, 14, and 21 after birth. Flies were placed inside a 50 mL transparent glass cylinder and, once acclimated, the cylinder was tapped down hard enough to knock all of the flies down to the bottom; after 10 s the number of flies able to reach three pre-established levels (below 5 cm—between 5 and 7.5 cm—above 10 cm) was counted. The protocol was repeated 10 times at 5-min intervals.

Immunofluorescence on Adult Brain. The dissection of each tissue analyzed was performed through the use of thin forceps in a dissection dish filled with 1% PBS solution, following a published protocol.⁶⁵ After fixation in PFA 4% (paraformaldehyde) for 20 min, the samples were cleaned from fat bodies and tracheal tube residues, in 1% PBS solution. In the end, they were moved to a 1.5 mL Eppendorf tube for the subsequent steps. The permeabilization of the

membranes used PBS Triton (PBST) 0.3% solution, which is a detergent used also in tissue culture analysis. The primary antibody anti-A β ₄₂ complexes (Alexa Fluor 594 #803018) were added to the blocking solution, at the concentration suggested 1:1000 and moved at 4 °C overnight. After washes in PBST for 20 min, each of the brains was stained with the secondary antibody (mouse FITC 1:250 Invitrogen #F2761). The samples were mounted in Fluoromount and the images were captured using a Leica confocal microscope, acquired with a 20 $\times$ air objective, and a 60 $\times$ mineral oil objective. The magnifications used the Nyquist theorem not to exceed the zoom and capture false signals. FluoView software was used for acquisition and Fiji (ImageJ) software for analysis.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acschemneuro.2c00357>.

Prediction of BBB penetration of compounds **7**, **10**, **16**, **17**, **22**, and **23**; chemical structures of reference compounds; inhibition of Tau₍₃₀₆₋₃₃₆₎ self-aggregation by **22** and **23**; compounds' purity and copies of representative chromatograms (**7**, **10**, **22** and **23**); and copies of ¹H NMR and ¹³C NMR spectra for final compounds (**1–24**) (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Maria Laura Bolognesi – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; orcid.org/0000-0002-1289-5361; Phone: +39 0512099718; Email: marialaura.bolognesi@unibo.it

Authors

Annachiara Gandini – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore di Studi Avanzati (SISSA), I-34136 Trieste, Italy; orcid.org/0000-0002-2888-9636

Ana Elisa Gonçalves – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; Pharmaceutical Sciences Postgraduate Program, Center of Health Sciences, Universidade do Vale do Itajaí, 88302-202 Itajaí, Santa Catarina, Brazil

Silvia Strocchi – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy

Claudia Albertini – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy

Jana Janočková – Biomedical Research Center, University Hospital Hradec Kralove, 500 00 Hradec Kralove, Czech Republic

Anna Tramarin – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy

Daniela Grifoni – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy

Eleonora Poeta – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy

Ondrej Soukup – Biomedical Research Center, University Hospital Hradec Kralove, 500 00 Hradec Kralove, Czech Republic; orcid.org/0000-0001-6376-8701

Diego Muñoz-Torrero – Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), E-08028 Barcelona, Spain; orcid.org/0000-0002-8140-8555

Barbara Monti – Pharmaceutical Sciences Postgraduate Program, Center of Health Sciences, Universidade do Vale do Itajaí, 88302-202 Itajaí, Santa Catarina, Brazil; orcid.org/0000-0003-0330-482X

Raimon Sabaté – Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, E-08028 Barcelona, Spain; orcid.org/0000-0003-3894-2362

Manuela Bartolini – Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; orcid.org/0000-0002-2890-3856

Giuseppe Legname – Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore di Studi Avanzati (SISSA), I-34136 Trieste, Italy; orcid.org/0000-0003-0716-4393

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acschemneuro.2c00357>

Author Contributions

M.L.B. conceived the study; A.G. performed compound synthesis and A.G. and C.A. performed compound characterization; A.E.G., E.P., and B.M. performed neurotoxicity experiments and analyzed data; J.J. and O.S. performed pharmacokinetic experiments; J.J., A.T., and M.B. performed the in vitro aggregation studies and analyzed data; R.S. performed the *E. coli* aggregation studies and R.S. and D.M.T. analyzed data; S.S., A.E.G., and D.G. performed *Drosophila* experiments and analyzed data; and M.L.B. and G.L. supervised A.G.'s work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

This work was conducted by A.E.G. during a scholarship at the University of Bologna, Italy, supported by the International Cooperation Program CAPES/ PDSE Process #88881.187586/ 2018-01. O.S. acknowledges the Ministry of Education, Youth and Sports of the Czech Republic (project ERDF no. CZ.02.1.01/0.0/0.0/18_069/0010054). DMT: grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033. M.L.B. and M.B. would also like to acknowledge the University of Bologna (RFO 2019) and the Italian Ministry of Education, Universities and Research (MIUR), for financial support.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors acknowledge Damian C. Crowther and the University of Cambridge, Department of Genetics Fly Facility

for the generous gift of Arctic A β ₄₂ flies. The technical support of Mr. Corrado Niro is also acknowledged.

■ ABBREVIATIONS USED

A β , amyloid β ; AD, Alzheimer's disease; BBB, blood–brain barrier; CGNs, cerebellar granule neurons; DMF, dimethylformamide; *E. coli*, *Escherichia coli*; EDDA, ethylenediamine diacetate; EMA, European Medicines Agency; ESI, electrospray ionization; FDA, Food and Drug Administration; HMTA, hexamethylenetetramine; IPTG, isopropyl 1-thio- β -D-galactopyranoside; MTDL, multitarget-directed ligand; MWI, microwave irradiation; NMR, nuclear magnetic resonance; PB, phosphate buffer; Pe, effective permeability; PPIs, protein–protein interactions; PRMs, protein recognition motifs; ThS, thioflavin S; ThT, thioflavin T; TLC, thin-layer chromatography; TMS, tetramethylsilane; TZD, 2,4-thiazolidinedione

■ REFERENCES

- (1) Alzheimer's Disease International. <https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/>. (7 December 2021).
- (2) Abyadeh, M.; Gupta, V.; Gupta, V.; Chitranshi, N.; Wu, Y.; Amirkhani, A.; Meyfour, A.; Sheriff, S.; Shen, T.; Dhiman, K.; et al. Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. *Aging Dis.* **2021**, *12*, 1964–1976.
- (3) Karran, E.; De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. *Nat. Rev. Drug Discovery* **2022**, *21*, 306–318.
- (4) Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer's disease drug development pipeline: 2020. *Alzheimers Dement.* **2020**, *6*, No. e12050.
- (5) Busche, M. A.; Hyman, B. T. Synergy between amyloid- β and tau in Alzheimer's disease. *Nat. Neurosci.* **2020**, *23*, 1183–1193.
- (6) Pickett, E. K.; Herrmann, A. G.; McQueen, J.; Abt, K.; Dando, O.; Tulloch, J.; Jain, P.; Dunnett, S.; Sohrabi, S.; Fjeldstad, M. P.; Calkin, W.; Murison, L.; Jackson, R. J.; Tzioras, M.; Stevenson, A.; d'Orange, M.; Hooley, M.; Davies, C.; Colom-Cadena, M.; Anton-Fernandez, A.; King, D.; Oren, I.; Rose, J.; McKenzie, C. A.; Allison, E.; Smith, C.; Hardt, O.; Henstridge, C. M.; Hardingham, G. E.; Spires-Jones, T. L. Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer's Disease. *Cell Rep.* **2019**, *29*, 3592–3604.
- (7) Busche, M. A.; Wegmann, S.; Dujardin, S.; Commins, C.; Schiantarelli, J.; Klickstein, N.; Kamath, T. V.; Carlson, G. A.; Nelken, I.; Hyman, B. T. Tau impairs neural circuits, dominating amyloid- β effects, in Alzheimer models in vivo. *Nat. Neurosci.* **2019**, *22*, 57–64.
- (8) Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. *J. Med. Chem.* **2008**, *51*, 347–372.
- (9) Malafaia, D.; Albuquerque, H.M.T.; Silva, A.M.S. Amyloid- β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. *Eur. J. Med. Chem.* **2021**, *214*, No. 113209.
- (10) Kranjc, A.; Bongarzone, S.; Rossetti, G.; Biarnés, X.; Cavalli, A.; Bolognesi, M. L.; Roberti, M.; Legname, G.; Carloni, P. Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. *J. Chem. Theory Comput.* **2009**, *5*, 2565–2573.
- (11) Staderini, M.; Legname, G.; Bolognesi, M. L.; Menéndez, J. C. Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. *Curr. Top. Med. Chem.* **2013**, *13*, 2491–2503.
- (12) Kolstoe, S. E.; Mangione, P. P.; Bellotti, V.; Taylor, G. W.; Tennent, G. A.; Deroo, S.; Morrison, A. J.; Cobb, A. J.; Coyne, A.; McCammon, M. G.; Warner, T. D.; Mitchell, J.; Gill, R.; Smith, M. D.; Ley, S. V.; Robinson, C. V.; Wood, S. P.; Pepys, M. B. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 20483–20488.
- (13) Dao, P.; Ye, F.; Liu, Y.; Du, Z. Y.; Zhang, K.; Dong, C. Z.; Meunier, B.; Chen, H. Development of Phenothiazine-Based Theranostic Compounds That Act Both as Inhibitors of β -Amyloid Aggregation and as Imaging Probes for Amyloid Plaques in Alzheimer's Disease. *ACS Chem. Neurosci.* **2017**, *8*, 798–806.
- (14) Gandini, A.; Bartolini, M.; Tedesco, D.; Martinez-Gonzalez, L.; Roca, C.; Campillo, N. E.; Zaldivar-Diez, J.; Perez, C.; Zuccheri, G.; Miti, A.; Feoli, A.; Castellano, S.; Petralla, S.; Monti, B.; Rossi, M.; Moda, F.; Legname, G.; Martinez, A.; Bolognesi, M. L. Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 β and Tau-Aggregation Inhibitors. *J. Med. Chem.* **2018**, *61*, 7640–7656.
- (15) Liu, H.; Zhong, H.; Liu, H.; Yao, X. Molecular dynamics simulations reveal the disruption mechanism of a 2,4-thiazolidinedione derivative C30 against tau hexapeptide (PHF6) oligomer. *Proteins* **2022**, *90*, 142–154.
- (16) Panek, D.; Wichur, T.; Godyń, J.; Pasięka, A.; Malawska, B. Advances toward multifunctional cholinesterase and β -amyloid aggregation inhibitors. *Future Med. Chem.* **2017**, *9*, 1835–1854.
- (17) Reinke, A. A.; Gestwicki, J. E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. *Chem. Biol. Drug Des.* **2007**, *70*, 206–215.
- (18) Cisek, K.; Cooper, G. L.; Huseby, C. J.; Kuret, J. Structure and mechanism of action of tau aggregation inhibitors. *Curr. Alzheimer Res.* **2014**, *11*, 918–927.
- (19) Bolognesi, M. L.; Bartolini, M.; Mancini, F.; Chiriano, G.; Ceccarini, L.; Rosini, M.; Milelli, A.; Tumiatti, V.; Andrisano, V.; Melchiorre, C. Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and anti-amyloid activities. *ChemMedChem* **2010**, *5*, 1215–1220.
- (20) Zhang, X.; Wang, Y.; Wang, S.-n.; Chen, Q.-h.; Tu, Y.-l.; Yang, X.-h.; Chen, J.-k.; Yan, J.-w.; Pi, R.-b.; Wang, Y. Discovery of a novel multifunctional carbazole–aminoquinoline dimer for Alzheimer's disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection. *Med. Chem. Res.* **2018**, *27*, 777–784.
- (21) Petrova, J.; Kálai, T.; Maezawa, I.; Altman, R.; Harishchandra, G.; Hong, H.-S.; Bricarello, D. A.; Parikh, A. N.; Lorigan, G. A.; Jin, L.-W.; et al. The influence of spin-labeled fluorene compounds on the assembly and toxicity of the A β peptide. *PLoS One* **2012**, *7*, No. e35443.
- (22) Nesterov, E. E.; Skoch, J.; Hyman, B. T.; Klunk, W. E.; Bacskaï, B. J.; Swager, T. M. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. *Angew. Chem., Int. Ed.* **2005**, *44*, 5452–5456.
- (23) Åslund, A.; Sigurdson, C. J.; Klingstedt, T.; Grathwohl, S.; Bolmont, T.; Dickstein, D. L.; Glimsdal, E.; Prokop, S.; Lindgren, M.; Konradsson, P.; Holtzman, D. M.; Hof, P. R.; Heppner, F. L.; Gandy, S.; Jucker, M.; Aguzzi, A.; Hammarström, P.; Nilsson, K. P. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. *ACS Chem. Biol.* **2009**, *4*, 673–684.
- (24) Cui, M. C.; Li, Z. J.; Tang, R. K.; Liu, B. L. Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for beta-amyloid plaques in Alzheimer's disease. *Bioorg. Med. Chem.* **2010**, *18*, 2777–2784.
- (25) Peng, K.-Y.; Chen, S.-A.; Fann, W.-S. Efficient Light Harvesting by Sequential Energy Transfer across Aggregates in Polymers of Finite Conjugational Segments with Short Aliphatic Linkages. *J. Am. Chem. Soc.* **2001**, *123*, 11388–11397.
- (26) Angyal, S. J.; Rassack, R. C. The Sommelet Reaction. *Nature* **1948**, *161*, 723.
- (27) Folmer-Andersen, J. F.; Buhler, E.; Candau, S.-J.; Joulie, S.; Schmutz, M.; Lehn, J.-M. Cooperative, bottom-up generation of rigid-rod nanostructures through dynamic polymer chemistry. *Polym. Int.* **2010**, *59*, 1477–1491.

- (28) Pouplana, S.; Espargaro, A.; Galdeano, C.; Viayna, E.; Sola, I.; Ventura, S.; Muñoz-Torrero, D.; Sabate, R. Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors. *Curr. Med. Chem.* **2014**, *21*, 1152–1159.
- (29) Espargaró, A.; Medina, A.; Di Pietro, O.; Muñoz-Torrero, D.; Sabate, R. Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. *Sci. Rep.* **2016**, *6*, 23349.
- (30) Viayna, E.; Sabate, R.; Muñoz-Torrero, D. Dual inhibitors of β -amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. *Curr. Top. Med. Chem.* **2013**, *13*, 1820–1842.
- (31) Pérez-Areales, F. J.; Di Pietro, O.; Espargaró, A.; Vallverdú-Queralt, A.; Galdeano, C.; Ragusa, I. M.; Viayna, E.; Guillou, C.; Clos, M. V.; Pérez, B.; Sabatè, R.; Lamuela-Raventós, R. M.; Luque, F. J.; Muñoz-Torrero, D. Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β -amyloid and tau anti-aggregating properties. *Bioorg. Med. Chem.* **2014**, *22*, 5298–5307.
- (32) Di Pietro, O.; Pérez-Areales, F. J.; Juárez-Jiménez, J.; Espargaró, A.; Clos, M. V.; Pérez, B.; Lavilla, R.; Sabatè, R.; Luque, F. J.; Muñoz-Torrero, D. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β -amyloid, tau, and cholinesterase pathologies. *Eur. J. Med. Chem.* **2014**, *84*, 107–117.
- (33) Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.; Sabatè, R.; Juárez-Jiménez, J.; Pérez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N. C.; Muñoz-Torrero, D. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. *J. Med. Chem.* **2014**, *57*, 2549–2567.
- (34) Sola, I.; Aso, E.; Frattini, D.; López-González, I.; Espargaró, A.; Sabatè, R.; Di Pietro, O.; Luque, F. J.; Clos, M. V.; Ferrer, I.; Muñoz-Torrero, D. Novel Levettiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. *J. Med. Chem.* **2015**, *58*, 6018–6032.
- (35) Caballero, A. B.; Espargaró, A.; Pont, C.; Busquets, M. A.; Estelrich, J.; Muñoz-Torrero, D.; Gamez, P.; Sabate, R. Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods. *Curr. Protein Pept. Sci.* **2019**, *20*, 563–576.
- (36) Wichur, T.; Więckowska, A.; Więckowski, K.; Godyń, J.; Jończyk, J.; Valdivieso, A.; Panek, D.; Pasieka, A.; Sabatè, R.; Knez, D.; Gobec, S.; Malawska, B. 1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease. *Eur. J. Med. Chem.* **2020**, *187*, No. 111916.
- (37) Bortolami, M.; Pandolfi, F.; Tudino, V.; Messori, A.; Madia, V. N.; De Vita, D.; Di Santo, R.; Costi, R.; Romeo, I.; Alcaro, S.; Colone, M.; Stringaro, A.; Espargaró, A.; Sabatè, R.; Scipione, L. New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and In Vitro and In Cellulo Evaluation. *ACS Chem. Neurosci.* **2021**, *12*, 4090–4112.
- (38) Pasieka, A.; Panek, D.; Szalaj, N.; Espargaró, A.; Więckowska, A.; Malawska, B.; Sabatè, R.; Bajda, M. Dual Inhibitors of Amyloid- β and Tau Aggregation with Amyloid- β Disaggregating Properties: Extended. *ACS Chem. Neurosci.* **2021**, *12*, 2057–2068.
- (39) Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmons, M.; Minguiñón, C.; González-Muñoz, G. C.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Muñoz-Torrero, D. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. *J. Med. Chem.* **2012**, *55*, 661–669.
- (40) Contestabile, A. Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro. *Cerebellum* **2002**, *1*, 41–55.
- (41) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier. *Eur. J. Med. Chem.* **2003**, *38*, 223–232.
- (42) Bartolini, M.; Naldi, M.; Fiori, J.; Valle, F.; Biscarini, F.; Nicolau, D. V.; Andrisano, V. Kinetic characterization of amyloid-beta 1-42 aggregation with a multimethodological approach. *Anal. Biochem.* **2011**, *414*, 215–225.
- (43) Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. Beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. *Biochem. Pharmacol.* **2003**, *65*, 407–416.
- (44) Stöhr, J.; Wu, H.; Nick, M.; Wu, Y.; Bhate, M.; Condello, C.; Johnson, N.; Rodgers, J.; Lemmin, T.; Acharya, S.; Becker, J.; Robinson, K.; Kelly, M.J.S.; Gai, F.; Stubbs, G.; Prusiner, S. B.; DeGrado, W. F. A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells. *Nat. Chem.* **2017**, *9*, 874–881.
- (45) Medina, L.; González-Lizárraga, F.; Dominguez-Meijide, A.; Ploper, D.; Parrales, V.; Sequeira, S.; Cima-Omori, M. S.; Zwickstetter, M.; Del Bel, E.; Michel, P. P.; Outeiro, T. F.; Raisman-Vozari, R.; Chehín, R.; Socias, S. B. Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity. *Front. Aging Neurosci.* **2021**, *13*, No. 635760.
- (46) Muqit, M. M. K.; Feany, M. B. Modelling neurodegenerative diseases in *Drosophila*: a fruitful approach? *Nat. Rev. Neurosci.* **2002**, *3*, 237–243.
- (47) Lu, B.; Vogel, H. *Drosophila* models of neurodegenerative diseases. *Annu. Rev. Pathol.* **2009**, *4*, 315–342.
- (48) Moloney, A.; Sattelle, D. B.; Lomas, D. A.; Crowther, D. C. Alzheimer's disease: insights from *Drosophila melanogaster* models. *Trends Biochem. Sci.* **2010**, *35*, 228–235.
- (49) Newman, T.; Sinadinos, C.; Johnston, A.; Sealey, M.; Mudher, A. Using *Drosophila* models of neurodegenerative diseases for drug discovery. *Expert Opin. Drug Discovery* **2011**, *6*, 129–140.
- (50) Pratim Bose, P.; Chatterjee, U.; Nerelius, C.; Govender, T.; Norström, T.; Gogoll, A.; Sandegren, A.; Göthelid, E.; Johansson, J.; Arvidsson, P. I. Poly-N-methylated amyloid beta-peptide (A β) C-terminal fragments reduce A β toxicity in vitro and in *Drosophila melanogaster*. *J. Med. Chem.* **2009**, *52*, 8002–8009.
- (51) Scherzer-Attali, R.; Pellarin, R.; Convertino, M.; Frydman-Marom, A.; Egoz-Matia, N.; Peled, S.; Levy-Sakin, M.; Shalev, D. E.; Caffisch, A.; Gazit, E.; Segal, D. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. *PLoS One* **2010**, *5*, No. e11101.
- (52) Caesar, I.; Jonson, M.; Nilsson, K. P.; Thor, S.; Hammarström, P. Curcumin promotes A β -fibrillation and reduces neurotoxicity in transgenic *Drosophila*. *PLoS One* **2012**, *7*, No. e31424.
- (53) McKoy, A. F.; Chen, J.; Schupbach, T.; Hecht, M. H. A novel inhibitor of amyloid β (A β) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. *J. Biol. Chem.* **2012**, *287*, 38992–39000.
- (54) Frenkel-Pinter, M.; Tal, S.; Scherzer-Attali, R.; Abu-Hussien, M.; Alyagor, I.; Eisenbaum, T.; Gazit, E.; Segal, D. Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity. *J. Alzheimers Dis.* **2016**, *51*, 165–178.
- (55) Frenkel-Pinter, M.; Tal, S.; Scherzer-Attali, R.; Abu-Hussien, M.; Alyagor, I.; Eisenbaum, T.; Gazit, E.; Segal, D. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. *Neurodegener. Dis.* **2017**, *17*, 73–82.
- (56) Crowther, D. C.; Kinghorn, K. J.; Miranda, E.; Page, R.; Curry, J. A.; Duthie, F. A.; Gubb, D. C.; Lomas, D. A. Intraneuronal A β , non-amyloid aggregates and neurodegeneration in a *Drosophila* model of Alzheimer's disease. *Neuroscience* **2005**, *132*, 123–135.
- (57) Jahn, T. R.; Kohlhoff, K. J.; Scott, M.; Tartaglia, G. G.; Lomas, D. A.; Dobson, C. M.; Vendruscolo, M.; Crowther, D. C. Detection of early locomotor abnormalities in a *Drosophila* model of Alzheimer's disease. *J. Neurosci. Methods* **2011**, *197*, 186–189.
- (58) Jonson, M.; Nyström, S.; Sandberg, A.; Carlback, M.; Michno, W.; Hanrieder, J.; Starkenberg, A.; Nilsson, K.P.R.; Thor, S.; Hammarström, P. Aggregated A β 1-42 Is Selectively Toxic for Neurons, Whereas Glial Cells Produce Mature Fibrils with Low Toxicity in *Drosophila*. *Cell Chem. Biol.* **2018**, *25*, 595–610.

(59) Albertini, C.; Naldi, M.; Petralla, S.; Strocchi, S.; Grifoni, D.; Monti, B.; Bartolini, M.; Bolognesi, M. From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. *Molecules* **2021**, *26*, 1112.

(60) Feng, B. Y.; Toyama, B. H.; Wille, H.; Colby, D. W.; Collins, S. R.; May, B. C.; Prusiner, S. B.; Weissman, J.; Shoichet, B. K. Small-Molecule Aggregates Inhibit Amyloid Polymerization. *Nat. Chem. Biol.* **2008**, *4*, 197–199.

(61) Lendel, C.; Bertocini, C. W.; Cremades, N.; Waudby, C. A.; Vendruscolo, M.; Dobson, C. M.; Schenk, D.; Christodoulou, J.; Toth, G. On The Mechanism of Nonspecific Inhibitors of Protein Aggregation: Dissecting the Interactions of Alpha-Synuclein with Congo Red and Lacmoid. *Biochemistry* **2009**, *48*, 8322–8334.

(62) Maccari, R.; Ottanà, R.; Curinga, C.; Vigorita, M. G.; Rakowitz, D.; Steindl, T.; Langer, T. Structure–Activity Relationships and Molecular Modelling of 5-arylidene-2,4-thiazolidinediones Active as Aldose Reductase Inhibitors. *Bioorg Med Chem* **2005**, *13*, 2809–2823.

(63) Brand, A. H.; Perrimon, N. Targeted Gene Expression as a Means of Altering Cell Fates and Generating Dominant Phenotypes. *Development* **1993**, *118*, 401–415.

(64) Costa, R.; Speretta, E.; Crowther, D. C.; Cardoso, I. Testing the Therapeutic Potential of Doxycycline in a *Drosophila Melanogaster* Model of Alzheimer Disease. *J. Biol. Chem.* **2011**, *286*, 41647–41655.

(65) Wu, J. S.; Luo, L. A Protocol for Dissecting *Drosophila Melanogaster* Brains for Live Imaging or Immunostaining. *Nat. Protoc.* **2006**, *1*, 2110–2115.

Recommended by ACS

The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease

Shakir Ahamad and Shah Nawaz A. Bhat

DECEMBER 09, 2022
JOURNAL OF MEDICINAL CHEMISTRY

READ 

Development of a Systematic Strategy toward Promotion of α -Synuclein Aggregation Using 2-Hydroxyisophthalamide-Based Systems

Aslam Uddin, Partha Hazra, *et al.*

OCTOBER 11, 2022
BIOCHEMISTRY

READ 

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease

Meihao Liang, Wenhui Huang, *et al.*

JULY 20, 2022
ACS OMEGA

READ 

Multiple Actions of H₂S-Releasing Peptides in Human β -Amyloid Expressing *C. elegans*

Rafat Ali, Sandeep Verma, *et al.*

NOVEMBER 09, 2022
ACS CHEMICAL NEUROSCIENCE

READ 

Get More Suggestions >